{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T17:54:58Z","timestamp":1774634098381,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s11523-026-01207-2","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T03:14:13Z","timestamp":1773371653000},"page":"299-307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Durvalumab: A Review in Limited-Stage Small Cell Lung Cancer"],"prefix":"10.1007","volume":"21","author":[{"given":"Nicole L.","family":"France","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahiya Y.","family":"Syed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"issue":"6","key":"1207_CR1","first-page":"602","volume":"73","author":"Z Megyesfalvi","year":"2023","unstructured":"Megyesfalvi Z, Gay CM, Popper H, et al. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin. 2023;73(6):602\u201352.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"1207_CR2","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/cncr.29098","volume":"121","author":"LA Byers","year":"2015","unstructured":"Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer. 2015;121(5):664\u201372.","journal-title":"Cancer"},{"key":"1207_CR3","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Small cell lung cancer version 2 2026. 2025. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sclc.pdf. Accessed 21 Jan 2026."},{"issue":"7","key":"1207_CR4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","volume":"32","author":"A-M Dingemans","year":"2021","unstructured":"Dingemans A-M, Fruh M, Ardizzoni A, et al. Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(7):839\u201353.","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"1207_CR5","doi-asserted-by":"publisher","first-page":"e400S","DOI":"10.1378\/chest.12-2363","volume":"143","author":"JR Jett","year":"2013","unstructured":"Jett JR, Schild SE, Kesler KA, et al. Treatment of small cell lung cancer: diagnosis and management of lung cancer 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(Suppl 5):e400S \u2013 e419.","journal-title":"Chest"},{"issue":"13","key":"1207_CR6","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1200\/JCO.22.01359","volume":"41","author":"J Bogart","year":"2023","unstructured":"Bogart J, Wang X, Masters G, et al. High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer: CALGB 30610 (Alliance)\/RTOG 0538. J Clin Oncol. 2023;41(13):2394\u2013402.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1207_CR7","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1097\/JTO.0b013e318293d8a4","volume":"8","author":"JK Salama","year":"2013","unstructured":"Salama JK, Hodgson L, Pang H, et al. A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. J Thorac Oncol. 2013;8(8):1043\u20139.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"1207_CR8","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1016\/j.cllc.2019.12.006","volume":"21","author":"S Senan","year":"2020","unstructured":"Senan S, Okamoto I, Lee GW, et al. Design and rationale for a phase III, randomized, placebo-controlled trial of durvalumab with or without tremelimumab after concurrent chemoradiotherapy for patients with limited-stage small-cell lung cancer: the ADRIATIC study. Clin Lung Cancer. 2020;21(2):e84\u20138.","journal-title":"Clin Lung Cancer"},{"issue":"14","key":"1207_CR9","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","volume":"391","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Spigel DR, Cho BC, et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med. 2024;391(14):1313\u201327.","journal-title":"N Engl J Med"},{"issue":"9","key":"1207_CR10","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069\u201386.","journal-title":"Cancer Discov"},{"key":"1207_CR11","unstructured":"AstraZeneca Pharmaceuticals LP. Imfinzi\u00ae (durvalumab) injection, for intravenous use: US prescribing information 2025. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761069s052lbl.pdf. Accessed 21 Jan 2026."},{"issue":"6","key":"1207_CR12","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s11523-021-00843-0","volume":"16","author":"ZT Al-Salama","year":"2021","unstructured":"Al-Salama ZT. Durvalumab: a review in extensive-stage SCLC. Target Oncol. 2021;16(6):857\u201364.","journal-title":"Target Oncol"},{"key":"1207_CR13","unstructured":"Genentech. Tecentriq\u00ae (atezolizumab) injection, for intravenous use. 2024. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761034s059lbl.pdf. Accessed 21 Jan 2026."},{"key":"1207_CR14","unstructured":"AstraZeneca AB. Imfinzi 50 mg\/ml concentrate for solution for infusion: summary of product characteristics. 2025. http:\/\/www.ema.europa.eu\/en\/documents\/product-information\/imfinzi-epar-product-information_en.pdf. Accessed 21 Jan 2026."},{"key":"1207_CR15","unstructured":"AstraZeneca Canada Inc. Imfinzi\u00ae (durvalumab for injection): notice of compliance. 2025. http:\/\/pdf.hres.ca\/dpd_pm\/00080178.PDF. Accessed 21 Jan 2026."},{"key":"1207_CR16","unstructured":"AstraZeneca UK Limited. Imfinzi 50 mg\/ml concentrate for solution for infusion: summary of product characteristics. 2025. http:\/\/www.medicines.org.uk\/emc\/product\/9495\/smpc\/print. Accessed 21 Jan 2026."},{"issue":"3 Suppl 1","key":"1207_CR17","doi-asserted-by":"publisher","first-page":"S203","DOI":"10.1016\/S1556-0864(25)00528-3","volume":"20","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Wang Q, Fang J, et al. Durvalumab (D) as consolidation therapy for limited-stage small-cell lung cancer (LS-SCLC): ADRIATIC China subgroup analysis [abstract no. 336P]. J Thorac Oncol. 2025;20(3 Suppl 1):S203\u20134.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"1207_CR18","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1111\/cas.70188","volume":"116","author":"Y Zenke","year":"2025","unstructured":"Zenke Y, Shiraishi Y, Goto Y, et al. Durvalumab post concurrent chemoradiotherapy in Japanese patients with limited\u2010stage small\u2010cell lung cancer in the phase 3 ADRIATIC trial. Cancer Sci. 2025;116(11):3171\u201384.","journal-title":"Cancer Sci"},{"key":"1207_CR19","doi-asserted-by":"publisher","unstructured":"Novello S, Cheng Y, Spigel D, et al. Patient-reported outcomes with consolidation durvalumab versus placebo following concurrent chemoradiotherapy in limited-stage small-cell lung cancer: results from the phase 3 ADRIATIC trial. J Thorac Oncol. 2026. https:\/\/doi.org\/10.1016\/j.jtho.2026.103564.","DOI":"10.1016\/j.jtho.2026.103564"},{"issue":"2 Suppl","key":"1207_CR20","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.ijrobp.2024.08.024","volume":"120","author":"P Iyengar","year":"2024","unstructured":"Iyengar P, Cheng Y, Spigel D, et al. Safety profile of durvalumab (D) as consolidation treatment (tx) in limited-stage small-cell lung cancer (LSSCLC) in ADRIATIC: focus on pneumonitis and immune mediated adverse events (imAEs) [abstract no. LBA 13]. Int J of Radiat Oncol Biol Phys. 2024;120(2 Suppl):S8-9.","journal-title":"Int J of Radiat Oncol Biol Phys."},{"issue":"1","key":"1207_CR21","first-page":"101","volume":"43","author":"GP Kalemkerian","year":"2025","unstructured":"Kalemkerian GP, Khurshid H, Ismaila N, et al. Erratum: systemic therapy for small cell lung cancer: ASCO guideline rapid recommendation update clinical insights. JCO Oncol Pract. 2025;43(1):101\u20135.","journal-title":"JCO Oncol Pract"},{"issue":"34","key":"1207_CR22","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1200\/JCO.2015.63.7918","volume":"33","author":"CM Rudin","year":"2015","unstructured":"Rudin CM, Ismaila N, Hann CL, et al. Treatment of small-cell lung cancer: American Society of Clinical Oncology endorsement of the American College of Chest Physicians guideline. J Clin Oncol. 2015;33(34):4106\u201311.","journal-title":"J Clin Oncol"},{"key":"1207_CR23","unstructured":"European Society for Medical Oncology. Durvalumab ADRIATIC ESMO-MCBS Scorecard. 2024. http:\/\/www.esmo.org\/guidelines\/esmo-mcbs\/esmo-mcbs-for-solid-tumours\/esmo-mcbs-scorecards?scorecard=483. Accessed 21 Jan 2026."},{"issue":"8","key":"1207_CR24","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.21037\/tlcr-2025-354","volume":"14","author":"K Liu","year":"2025","unstructured":"Liu K, Zhu Y, Zhu H. International cost-effectiveness analysis of durvalumab consolidation treatment after chemoradiotherapy for patients with limited-stage small-cell lung cancer. Transl Lung Cancer Res. 2025;14(8):2942\u201353.","journal-title":"Transl Lung Cancer Res"},{"key":"1207_CR25","doi-asserted-by":"publisher","DOI":"10.1200\/GO-25-00225","volume":"11","author":"CT Jani","year":"2025","unstructured":"Jani CT, Manoharan A, Han S, et al. Cost-effectiveness analysis of durvalumab in limited-stage small cell lung cancer in the United States. JCO Glob Oncol. 2025;11:e2500225.","journal-title":"JCO Glob Oncol."},{"key":"1207_CR26","doi-asserted-by":"publisher","first-page":"1643022","DOI":"10.3389\/fonc.2025.1643022","volume":"15","author":"H Zhang","year":"2025","unstructured":"Zhang H, Liu Y, Cai B, et al. Durvalumab consolidation therapy in patients with stage III small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis. Front Oncol. 2025;15:1643022.","journal-title":"Front Oncol"},{"key":"1207_CR27","unstructured":"National Institute for Health and Care Excellence (NICE). Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy. 2025. http:\/\/www.nice.org.uk\/guidance\/ta1099. Accessed 21 Jan 2026."},{"key":"1207_CR28","unstructured":"AstraZeneca. Imfinzi approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer [media release]. 5 December 2024. http:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2024\/imfinzi-approved-in-us-for-limited-stage-sclc.html."},{"key":"1207_CR29","unstructured":"AstraZeneca. Imfinzi approved in the EU as first and only immunotherapy for limited-stage small cell lung cancer [media release]. 17 March 2025. http:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2025\/imfinzi-approved-in-eu-for-limited-stage-sclc.html."},{"issue":"8 Suppl 2","key":"1207_CR30","doi-asserted-by":"publisher","first-page":"CT094","DOI":"10.1158\/1538-7445.AM2025-CT094","volume":"85","author":"C Hann","year":"2025","unstructured":"Hann C, Cheng Y, Spigel D, et al. Durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC): outcomes by PD-L1 expression in ADRIATIC [abstract no. CT094]. Cancer Res. 2025;85(8 Suppl 2).","journal-title":"Cancer Res"},{"issue":"3 Suppl 1","key":"1207_CR31","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.1016\/S1556-0864(25)00489-7","volume":"20","author":"S Senan","year":"2025","unstructured":"Senan S, Cheng Y, Spigel DR, et al. Patterns of disease progression with durvalumab (D) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC): results from ADRIATIC [abstract no. 297MO]. J Thorac Oncol. 2025;20(3 Suppl 1):S181\u20132.","journal-title":"J Thorac Oncol"},{"key":"1207_CR32","doi-asserted-by":"publisher","unstructured":"Jin X, Zhao W, Li G, et al. Immunotherapy for limited-stage small cell lung cancer: innovative treatments and future perspectives. Cancer Control. 2025. https:\/\/doi.org\/10.1177\/10732748251334434.","DOI":"10.1177\/10732748251334434"},{"key":"1207_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.110837","volume":"207","author":"D Ruysscher","year":"2025","unstructured":"Ruysscher D, Wauters E, Jendrossek V, et al. Diagnosis and treatment of radiation induced pneumonitis in patients with lung cancer: an ESTRO clinical practice guideline. Radiother Oncol. 2025;207:110837.","journal-title":"Radiother Oncol"},{"issue":"9","key":"1207_CR34","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","volume":"3","author":"R Stewart","year":"2015","unstructured":"Stewart R, Morrow M, Hammond SA, et al. Identification and characterization of MEDI4736, an antagonistic anti\u2013PD-L1 monoclonal antibody. Cancer Immunol Res. 2015;3(9):1052\u201362.","journal-title":"Cancer Immunol Res"},{"key":"1207_CR35","unstructured":"European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). Imfinzi assessment report. 2018. http:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/imfinzi-epar-public-assessment-report_en.pdf. Accessed 21 Jan 2026."}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01207-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01207-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01207-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:57:56Z","timestamp":1774630676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01207-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1207"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01207-2","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N. L. France and Y. Y. Syed are salaried employee of Adis International Ltd\/Springer Nature and declare no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}